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Abstract
Aims/hypothesis Sphingolipid synthesis is typically initiat-
ed by the conjugation of L-serine and palmitoyl-CoA, a
reaction catalysed by serine palmitoyltransferase (SPT).
SPT can also metabolise other acyl-CoAs (C12 to C18) and
other amino acids such as L-alanine and glycine, giving rise
to a spectrum of atypical sphingolipids. Here, we aimed to
identify changes in plasma levels of these atypical
sphingolipids to explore their potential as biomarkers in
the metabolic syndrome and diabetes.
Methods We compared the plasma profiles of ten sphingoid
bases in healthy individuals with those of patients with the
metabolic syndrome but not diabetes, and diabetic patients
(n=25 per group). The results were verified in a streptozo-
tocin (STZ) rat model. Univariate and multivariate statisti-
cal analyses were used.
Results Deoxysphingolipids (dSLs) were significantly ele-
vated (p ¼ 5 106) in patients with the metabolic
syndrome (0.11±0.04 μmol/l) compared with controls
(0.06±0.02 μmol/l) but did not differ between the metabolic
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syndrome and diabetes groups. Levels of C16-sphingosine-
based sphingolipids were significantly lowered in diabetic
patients but not in patients with the metabolic syndrome but
without diabetes (p=0.008). Significantly elevated dSL
levels were also found in the plasma and liver of STZ rats.
A principal component analysis revealed a similar or even
closer association of dSLs with diabetes and the metabolic
syndrome in comparison with the established biomarkers.
Conclusions/interpretation We showed that dSLs are sig-
nificantly elevated in patients with type 2 diabetes mellitus
and non-diabetic metabolic syndrome compared with
healthy controls. They may, therefore, be useful novel
biomarkers to improve risk prediction and therapy moni-
toring in these patients.
Keywords Atypical sphingolipids . Biomarker .
Deoxysphingolipids . Metabolic syndrome . Type 2 diabetes
mellitus
Abbreviations
ALT Alanine aminotransferase
doxSA Deoxysphinganine
doxSO Deoxysphingosine
dSL Deoxysphingolipid
DPN Diabetic peripheral neuropathy
HSAN1 Hereditary sensory and autonomic
neuropathy type 1
OPLS-DA Orthogonal partial least square-discriminant
analysis
PCA Principal component analysis
ROC Receiver operating characteristic
SA Sphinganine
SO Sphingosine
SPT Serine palmitoyltransferase
STZ Streptozotocin
VIP Variable importance for the projection
Introduction
The pathogenesis of diabetes mellitus type 2 is characterised
by the development of insulin resistance, frequently because
of excess body fat, that is initially overcome by increased
insulin secretion and—after several years—a subsequent
decrease in the functional pancreatic beta cell mass that can
no longer compensate for insulin resistance [2–4]. Insulin
resistance or the compensating hyperinsulinaemia leads to
the manifestation of a cluster of risk factors, including
hyperglycaemia, hypertriacylglycerolaemia, low plasma
levels of HDL-cholesterol and arterial hypertension, that
has been termed the metabolic syndrome. Although much
progress [5] has been made in the understanding of the
mutual relationships between obesity, insulin resistance, type
2 diabetes and atherosclerosis, the complete picture remains
elusive. In the last years the carbohydrate-centred view of the
pathogenesis of diabetes has widened to include different
classes of lipids [5–7] and inflammatory factors [8].
Mounting evidence suggests that sphingolipids play a role
in the pathogenesis of insulin resistance and diabetes [9–11].
In particular, ceramides have been suggested to be important
in the development of insulin resistance. For instance,
inhibition of ceramide synthesis restored insulin sensitivity
in palmitate-induced insulin resistance in mice [12].
Sphingolipids comprise a heterogeneous class of lipids
that are derived from the aliphatic amino-alcohol sphingo-
sine, which is commonly formed from the precursors
L-serine and palmitoyl-CoA (electronic supplementary mate-
rial [ESM] Fig. 1). This reaction is catalysed by the enzyme
serine palmitoyltransferase (SPT). In addition to these
substrates, SPT metabolises other acyl-CoAs with carbon
chain lengths in the range C12 to C18 [13]. Moreover, SPT
also has flexibility in the use of other amino acid substrates
such as L-alanine and glycine [14, 15], which generate an
atypical category of 1-deoxysphingoid bases. Whereas the
conjugation of alanine forms deoxysphinganine (doxSA),
the use of glycine results in the formation of deoxymethyl-
sphinganine. These two metabolites can be N-acylated to
form deoxysphingolipids (dSLs), but cannot be further
metabolised to complex sphingolipids because of the missing
C1-hydroxyl group [16]. Consequently, these metabolites
cannot be degraded by the canonical sphingolipid degradation
pathway, which requires the formation of sphingosine-1-
phosphate as a catabolic intermediate. Whereas dSLs occur
ubiquitously at low levels in human plasma, levels are greatly
increased in hereditary sensory and autonomic neuropathy
type 1 (HSAN1; OMIM162400), an inherited sensory
neuropathy caused by missense mutations in SPT [15].
Physiologically, de novo sphingolipid synthesis represents
a metabolic cross point that interconnects lipid, amino acid
and thereby indirectly also carbohydrate metabolism. Fluctu-
ations in fatty acid and thereby acyl-CoA concentrations are
reflected in altered carbon-chain compositions of the sphin-
goid bases [12, 17]. Another node connects serine and
alanine metabolism to the sphingolipid metabolism. Serine is
formed from 3-phosphoglycerate whereas alanine can be
converted from and to pyruvate through alanine aminotrans-
ferase (ALT) in a reversible transaminase reaction. Hence,
the precursors for both amino acids are generated during
glycolysis and thereby provide a functional link between
sphingolipid and carbohydrate metabolism. In this respect, it
is noteworthy that alanine is the major gluconeogenic amino
acid, with important roles in obesity and diabetes [18, 19].
In light of these metabolic connections and the increas-
ing evidence that certain sphingolipid molecules have roles
in the pathogenesis of insulin resistance and diabetes, we
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compared the plasma sphingoid base profiles of healthy
humans with those of patients with the metabolic syndrome
but not diabetes and of patients with type 2 diabetes
mellitus. The observed differences were further confirmed
in an animal model of diabetes.
Methods
Patients
A sex- and age-matched nested cohort of 25 patients with
non-diabetic metabolic syndrome, 25 patients with the
metabolic syndrome and type 2 diabetes mellitus, and 25
controls without diabetes or the metabolic syndrome was
selected from a previously described study cohort [20] of
the Vorarlberg Institute for Vascular Investigation and
Treatment (VIVIT; Feldkirch, Austria). The samples were
derived from a larger cohort of unselected white patients
undergoing coronary angiography for the evaluation of
suspected coronary artery disease. Only patients with
negative angiographic results were enrolled in this study.
The age range was 55–69 years. The angiographers were not
aware of plasma sphingolipid levels. The study was approved
by the Ethics Committee of the University of Innsbruck and
all participants gave written informed consent.
Table 1 Baseline characteristics and results
Characteristic Control (n=25) Metabolic syndrome
(n=25)
Diabetes (n=25) Kruskal–Wallis p value Mann–Whitney U p value
C vs MetS MetS vs D
Age 61.19±4.28 62.13±5.02 61.56±4.64 0.771 0.50 0.567
Female (%) 40 40 40 1.000
Smoking (%) 64 56 60 0.846
Wcf (cm) 98.24±12.10 105.84±8.23 110.80±11.97 3.70×10−4 0.004 0.051
BMI 28.19±4.49 30.13±3.01 32.21±4.83 0.006 0.05 0.09
Fasting glucose (mmol/l) 5.26±0.56 5.64±0.57 9.59±4.16 1.94×10−9 0.03 4.29×10−7
HbA1c (%) 5.60±0.33 5.76±0.34 7.79±2.04 4.71×10
−10 0.17 9.52×10−8
HbA1c (mmol/l) 37.71 39.45 61.64
Cholesterol (mmol/l) 5.26±1.24 4.99±1.30 4.98±1.44 0.777 0.49 0.861
LDL-cholesterol (mmol/l) 3.35±0.96 3.45±1.00 3.16±1.22 0.449 0.52 0.269
HDL-cholesterol (mmol/l) 1.80±0.69 1.15±0.21 1.31±0.32 1.60×10−5 2.37×10−6 0.132
TG (mmol/l) 1.10±0.37 2.51±0.83 2.21±1.47 1.96×10−7 1.38×10−8 0.067
SBP (mmHg) 126.80±12.47 133.84±15.23 135.52±15.92 0.081 0.12 0.44
DBP (mmHg) 78.80±8.50 83.92±9.41 82.24±8.99 0.161 0.06 0.565
AST 28.56±8.60 30.84±24.10 25.84±8.43 0.388 0.38 0.662
ALT 29.92±15.71 34.76±24.54 31.68±13.25 0.650 0.35 0.907
Creatinine 0.84±0.18 0.92±0.21 0.81±0.23 0.144 0.20 0.06
GFR 100.65±11.53 95.26±15.30 100.77±15.68 0.316 0.22 0.184
C16SO (μmol/l) 8.31±4.49 8.38±2.25 6.37±2.82 0.041 0.55 0.008
C16SA (μmol/l) 0.23±0.13 0.23±0.10 0.26±0.14 0.749 0.84 0.491
C17SO (μmol/l) 4.66±2.42 4.02±1.10 3.71±1.48 0.387 0.64 0.29
C17SA (μmol/l) 0.15±0.07 0.14±0.05 0.14±0.05 0.960 0.82 0.961
SO (μmol/l) 88.83±27.23 81.66±21.28 81.54±23.89 0.622 0.34 0.793
SA (μmol/l) 2.17±0.9 2.20±0.77 2.57±1.14 0.473 0.82 0.299
C20SO (μmol/l) 0.20±0.08 0.19±0.06 0.19±0.05 0.727 0.46 0.839
doxSO (μmol/l) 0.15±0.09 0.23±0.09 0.24±0.13 2.14×10−4 3×10−5 0.839
doxSA (μmol/l) 0.06±0.02 0.11±0.04 0.12±0.05 3.92×10−6 5×10−6 0.808
C18SA-diene (μmol/l) 20.79±8.17 18.27±5.74 16.42±6.80 0.148 0.36 0.273
Values are expressed as means±SD or percentages for scale or categorical variables, respectively
p values were calculated with Kruskal–Wallis test for all three group, and with the Mann–Whitney U test for two group comparisons; after
Bonferroni correction a p value of 0.002 corresponded to a significance level of 0.05. For the categorical variable, asymptotic two-sided p values
for χ2 are shown
AST, aspartate aminotransferase; C, controls; D, diabetic patient group; DBP, diastolic BP; MetS, metabolic syndrome group; SBP, systolic BP;
TG, triacylglycerol; Wcf, waist circumference
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According to National Cholesterol Education Program-
Adult Treatment Panel III criteria, non-diabetic metabolic
syndrome was diagnosed if three or more of the following
criteria were fulfilled: waist circumference >102 cm in men
or >88 cm in women; triacylglycerols ≥1.7 mmol/l
(150 mg/dl); HDL-cholesterol <1.0 mmol/l (40 mg/dl) in
men or <1.3 mmol/l (50 mg/dl) in women; blood pressure
≥130/≥85mmHg; and fasting glucose ≥6.1 mmol/l (110 mg/dl)
but <7 mmol/l. Type 2 diabetes mellitus was diagnosed
by either fasting glucose levels ≥7 mmol/l (126 mg/dl),
or plasma glucose levels ≥11.1 mmol/l (200 mg/dl) 2 h
after an oral challenge with 75 g glucose, or previously
diagnosed diabetes. Controls were defined by the
absence of both non-diabetic metabolic syndrome and
type 2 diabetes mellitus
Clinical chemistry
Venous blood samples were collected after an overnight fast
of at least 12 h before angiography was performed, and
laboratory measurements were performed from fresh serum
samples. The serum levels of triacylglycerols, total choles-
terol and HDL-cholesterol were determined by using
enzymatic hydrolysis and precipitation techniques (triacyl-
glycerol glycerol phosphate oxidase-p-aminophenazone
(GPO-PAP), cholesterol oxidase phenol 4-aminoantipyrine
peroxidase (CHOD/PAP), QuantolipLDL, QuantolipHDL;
Roche, Basel, Switzerland) on a Hitachi-Analyzer 717 or
911. Level of HbA1c was determined by high-performance
liquid chromatography (LC) on a Menarini-Arkray KDK
HA 8140 (Arkray KDK, Kyoto, Japan). Clinical chemistry
variables were measured on a Hitachi 717 or 911 system
(Roche).
Animal model
Male Sprague–Dawley rats (180–200 g, Charles River,
Calco, Italy) were housed in pairs. Animal room tempera-
ture and relative humidity were set at 22±2°C and 55±
10%, respectively. Artificial lighting provided a 12 h light–
dark cycle (07:00–19:00 hours). The animals had free
access to diet and water. Diabetes was induced in rats fasted
overnight by a single i.p. injection of 60 mg/kg of
streptozotocin (STZ) dissolved in sodium citrate buffer
(pH 4.5). The control rats were injected with vehicle.
Hyperglycaemia was confirmed by measuring glycosuria
72 h after STZ injection, using Keto-Diabur test 5000 strips
(Roche Diagnostics, Spa, Italy). Only animals with glycos-
uria >5% were classified as diabetic and included in the
study. Body weight and blood glucose concentration,
determined by tail bleeding using strips (Ascensia Elite;
Bayer, Basel, Switzerland), were measured weekly. Imme-
diately after killing the animals, liver and muscle (gastroc-
nemius) were carefully dissected out and immediately
frozen in liquid N2.
Quantification of sphingoid bases
The lipids were analysed as described before [15, 21].
Tissue samples were homogenised in lysis buffer
(25 mmol/l HEPES pH 8, 0.2% Triton X-100 [vol./vol.])
using a Precellys 24 tissue homogenizer (Bertin Technologies,
Montigny-le-Bretonneux, France). Briefly, 100 μl plasma or
tissue homogenate containing 80 μg extracted protein was
added to 1 ml extraction buffer (2:1) methanol–KOH/
chloroform and spiked with 200 pmol internal standard
C20-sphinganine (C20SA; Avanti Polar Lipids, Alabaster,
AL, USA).
The extracted dried lipids were acid hydrolysed using
methanolic HCl (1 mol/l HCl/10 mol/l water in methanol)
and heat (65°C, 16 h) to release the sphingoid base
backbones. This was followed by a second extraction. LC/
MS analysis was performed as described earlier [15]. Lipids
were separated on a C18 column (Uptispere 120 Å, 5 μm,
125×2 mm; Interchim, Montluçon, France) and analysed
by an MS detector (LCQ, Thermo, Wohlen, Switzerland).
The samples were measured as singletons for each
participant. Inter- and intra-assay CVs were between 5%
and 20% for each sphingoid base.
The sphingoid bases analysed included C16SO, C16SA,
C17SO, C17SA, C18SO, C18SA, C20SO, C18SA-diene,
doxSA and doxSO.
Statistics
Mean comparison and receiver operating characteristic
curve analyses The original dataset was imported into
SPSS 16.0 (SPSS Switzerland, Zurich, Switzerland). As
some of the variables measured did not follow normal
distribution, even after transformations, non-parametric
tests were used. The Kruskal–Wallis test was used to
compare all three groups. The Mann–Whitney U test was
used for comparisons between two groups, followed by the
Bonferroni correction. Spearman correlations were calcu-
lated. Receiver operating characteristic (ROC) curve analy-
sis was performed and the two-tailed asymptotic p value
was calculated for the ROC AUCs.
Orthogonal partial least square-discriminant analysis Or-
thogonal partial least square-discriminant analysis (OPLS-
DA) [22, 23] was used as a multivariate predictive and
regression method, based on the concepts of principal
component analysis (PCA). In PCA, a large number of
correlated variables (e.g. clinical, clinical chemistry and
sphingolipid variables) are summarised into a smaller
number of uncorrelated ones called principal components.
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Thus, the correlation structures are preserved while reduc-
ing the number of variables. In contrast to PCA, which does
not consider class membership, in OPLS-DA the group
information is included (control, the non-diabetic metabolic
syndrome and diabetes) as a Y variable. OPLS-DA therefore
summarises the data into a predictive component, max-
imising the between-group variation and an orthogonal
component(s) describing the within-group variation. The
predictive component describes the variations in X that
correlate with Y. The orthogonal component describes the
systematic variations within each group that do not
correlate with Y, thereby removing the noise data from the
predictive component.
For any modelling technique, model evaluation is
necessary before any inferences are made. R2Y reports
the fit of the model to the original dataset and Q2Y reports
the predictive ability of the model calculated by cross
validation. Cross validation is performed by dividing the
whole dataset into multiple random groups and then
predicting the class assignment of members of each group
at a time.
The dataset was imported into SIMCA-P +12.0.1.0
(Umetrics, Umeå, Sweden) for the calculations. The groups
(control, non-diabetic metabolic syndrome and diabetes)
were assigned as classes. Variables that did not follow the
normal distribution were log transformed before model
fitting. As some variables did not follow the normal
distribution after log transformation, models were fitted
twice, once with the log-transformed variables and another
time without any transformations. The model evaluation
parameters and interpretations did not differ in both cases.
Therefore, the values for all the variables without any
transformations were used. As the values for the variables
had different scales, the dataset was normalised in unit
variance and centred around the mean. OPLS-DA models
were fitted for the classes to get the highest R2Y and Q2Y
values. Models were used to compare two groups only at a
time (control vs non-diabetic metabolic syndrome and non-
diabetic metabolic syndrome vs diabetes). We did not use
three groups as a Y variable as this would have made the
interpretations of the model results more complex.
As PCA-based methods are sensitive to outliers, Hotel-
ling’s T2 and distance to the model, DmodX, were used to
detect outliers. Hotelling’s T2 is a generalisation of the
t distribution for the multivariate case and is usually
visualised in score plots. Score plots show on the x-axis
the scores of the predictive component describing the
between-group variation and on the y-axis the scores of
the orthogonal component describing the within-group
variation. Tolerance ellipse is drawn in score plots outlining
the 95% probability of the Hotelling’s T2 distribution.
Scores for observations situated outside the tolerance
ellipse can be considered outliers. Moreover, DModX
shows the distance to the model in the X space in a way
similar to the residuals in the linear regression models. A
critical value D-Crit of 0.05 was set as a limit for outlier
detection. After outliers were detected, models were fitted
twice, excluding and including the outliers. In the current
study, no difference was found in the model evaluation
parameters or any of the results upon inclusion or exclusion
of the outliers. Therefore, models without outlier removal
were used for the interpretation.
Cross validation was performed for each model with seven
groups. The cross validation ANOVA was calculated along
with misclassification tables and Fisher’s probabilities.
Results
For this study, we analysed plasma samples from patients
in three pre-defined subgroups, each consisting of 25 sex-
and age-matched patients with either manifest type 2
diabetes mellitus, the metabolic syndrome but no manifest
diabetes mellitus, or without diabetes mellitus or the
metabolic syndrome (controls). The results are summarised
in Table 1.
Sphingoid bases in plasma are usually N-acylated and
conjugated with different headgroups, giving rise to a
great variety of different sphingolipid species. To analyse
the sphingoid base composition of these metabolites we
subjected the extracted lipids to sequential acid and base
hydrolysis to remove the N-acyl chain and head group.
The resulting free sphingoid bases were analysed by
LC/MS.
The most abundant sphingoid base in human plasma
was C18-sphingosine (C18SO) followed by C18SA-diene,
C16-sphingosine (C16SO) and C17-sphingosine (C17SO).
Generally, dSLs were recovered as quantitatively minor
fractions, representing 0.1–0.3% of the total sphingoid
bases
Plasma concentrations of total dSLs were significant-
ly higher for the non-diabetic metabolic syndrome
group (0.11±0.04 μmol/l) compared with controls
(0.06±0.02 μmol/l) but did not differ between the
metabolic syndrome and diabetic groups (Table 1). This
elevation remained significant after the Bonferroni cor-
rection for multiple testing. In contrast, C16SO levels were
found to be significantly lower (p=0.008) in diabetic
patients (6.37±2.82 μmol/l) in comparison with partici-
pants with non-diabetic metabolic syndrome (8.38±
2.25 μmol/l). However, this decrease missed the signifi-
cance limit after Bonferroni correction in which a
significance level of 0.05 corresponds to a p value of
0.002. Concentrations of other sphingoid bases were not
significantly different between the three groups.
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A correlation matrix of all variables (clinical data,
clinical chemistry measurements along with sphingoid base
backbone measurements) showed a significant correlation
of the serine-based sphingolipids (C16, C17 or C18SA or SO
and C18SA-diene) with LDL-cholesterol and total choles-
terol but correlated less strongly with HDL-cholesterol. In
contrast, the alanine-based dSLs showed a strong correla-
tion with the variables related to the metabolic syndrome,
such as waist circumference and triacylglycerols (ESM
Fig. 2). Therefore, we were interested to see whether the
increased dSL levels are associated with hyperglycaemia
per se or rather with insulin resistance. To address this issue
we analysed plasma, liver and muscle tissue samples from
STZ-treated rats (Table 2). Although beta cell failure and
not insulin resistance is the basis of the STZ rat model, we
found significantly elevated dSL levels in plasma and liver
from STZ rats (Table 2, Fig. 1). No dSLs were detected in
muscle tissue. This suggests that plasma dSLs are primarily
elevated in association with hyperglycaemia and are
probably of hepatic origin.
An OPLS-DAwas used to estimate the importance of the
individual variables as discriminating biomarkers. Both
models (control vs non-diabetic metabolic syndrome and
non-diabetic metabolic syndrome vs diabetes) showed good
fit and predictive power. Therefore, they are valid for
discrimination (ESM Table 1).
In score plots (Fig. 2a,b), clustering into separate groups
was preserved after reducing the whole dataset into a single
predictive component (shown on the x-axis) and an
orthogonal one (shown on the y-axis). Loading plots
(Fig. 2c,d) show the weights of each of the original
variables in the model and hence their individual contribu-
tions to the disease state. In the control vs metabolic
syndrome loading plot (Fig. 2c), triacylglycerols, doxSA,
doxSO, and diastolic and systolic blood pressure contrib-
uted to the metabolic syndrome state model (95% CI>0)
whereas elevated HDL-cholesterol contributed to the
control state model (95%CI<0). This confirms the biolog-
ical and clinical validity of the model, as elevated
triacylglycerols, low HDL-cholesterol and hypertension
are key features of the metabolic syndrome. DoxSA and
doxSO were identified as the second and fourth most
important contributors to the metabolic syndrome model,
just after triacylglycerols and HDL-cholesterol, respective-
ly, but above glucose, waist circumference and systolic
blood pressure. In the metabolic syndrome vs diabetes
Table 2 Results of STZ rat
tissue and plasma analysis
Values are shown as mean±SD
p values were calculated
with Mann–Whitney U test:
*p<0.05; ***p<0.001
C, controls; ND, not detected;
STZ, STZ-treated rats
Variable Liver (pmol/100 μg protein) Muscle (pmol/100 μg
protein)
Plasma (μmol/l)
C STZ C STZ C STZ
Glucose
(mmol/l)
– – – – 8.8±0.4 53.8±3.3***
C16SO 3.4±0.8 3.1±0.7 1.5±0.23 1.4±0.24 0.06±0.02 0.09±0.07
C17SO 15.7±3.3 13±2.5 4.2±0.44 5.0±1.2 0.3±0.1 0.4±0.1
C18SA-diene 64.1±10.6 78.1±26.1 11.2±2.3 21.5±10.3* 2.6±0.4 5.0±0.9*
SO 1,130±189 1,127±252 180±25.4 262±106* 24.3±7.6 29.1±4.8
SA 40.3±9.4 66.4±29* 9.1±1.8 8.1±2.6 1.0±0.5 1.6±0.6*
C20SO 10.8±4.4 11.4±2 6.5±0.6 6.7±1.6 0.1±0.08 0.15±0.9
DoxSA 0.2±0.08 0.4±0.12*** ND ND 0.01±0.003 0.12±0.9***
DoxSO ND ND ND ND ND ND
do
xS
A
(pm
ol/
µg
 pr
ote
in)
0.000
0.002
0.004
0.006
0.008
0.010 ba
***
***
do
xS
A
(µm
ol/
l)
0.0
0.1
0.2
0.3
0.4
0.5
C STZC STZ
Fig. 1 DoxSA levels are signifi-
cantly (p<0.001) elevated in liver
tissue (a) and plasma (b) of STZ
rats (STZ) compared with con-
trols (C)
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model (Fig. 2d), we found elevated fasting glucose and HbA1c
concentrations, together with low C16SO and creatinine levels,
to be the contributors to the diabetes state model.
Variable importance for the projection (VIP) plots
(Fig. 2e,f) show the contribution of each variable to the
variation in both the X space and the Y space (and hence
their correlations with other variables and the control or
disease state). A coefficient value >1 signifies that the
variable is important. For the control vs metabolic
syndrome model (Fig. 2e), the VIP plot showed the
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Fig. 2 a,b Score plots of OPLS-DAmodels: (a) control vs non-diabetic
metabolic syndrome; (b) non-diabetic metabolic syndrome vs type 2
diabetes. Individual observations are shown as: black triangles, controls;
white triangles, the metabolic syndrome; black rhombus, type 2
diabetes. On the x-axis, the scores for each individual in the predictive
principal component (t[1]) are shown, while the y-axis shows the scores
for each individual in the orthogonal component (to[1]). Thus,
variations on the x-axis reflect the between-group separation while
variations on the y-axis show the within-group variations (noise). The
tolerance ellipse corresponds to 95% of the Hotelling’s T2 multivariate
distribution. c,d Loading column plots of OPLS-DA models control vs
the metabolic syndrome (c) and the metabolic syndrome vs diabetes (d).
The variables are shown on the x-axis, while the loading coefficients
(weights) are shown on the y-axis. The weights represent the
contribution of each variable to the model component scores. Variables
with larger weights contribute more to the model. Error bars represent
95% CIs for calculated weights. e,f VIP plot for OPLS-DA models:
control vs the metabolic syndrome (e) and the metabolic syndrome vs
diabetes (f). The variables are shown on the x-axis, while VIP
coefficients are shown on the y-axis. The VIP coefficients plot shows
the summation of all the weights for each X variable to predict Y and
hence denoting the importance of each X variable. AST, aspartate
aminotransferase; Chol, cholesterol; Crea, creatinine; DBP, diastolic BP;
HDL, HDL-cholesterol; LDL, LDL-cholesterol; SBP, systolic BP;
T2DM, type 2 diabetes mellitus; TG, triacylglycerol; Wcf, waist
circumference
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highest VIP coefficients for triacylglycerols, doxSA,
HDL-cholesterol and doxSO. A slight importance (VIP
coefficient slightly >1) was noticed for diastolic pressure
and fasting glucose. For the metabolic syndrome vs type 2
diabetes mellitus model (Fig. 2f) a significant impor-
tance of HbA1c, glucose and C16SO was seen. VIP
coefficients were also >1 for BMI, HDL-cholesterol and
creatinine.
In summary, the OPLS-DA analysis revealed that
triacylglycerols, doxSA, doxSO and HDL-cholesterol are
the best explanatory variables for the non-diabetic meta-
bolic syndrome, while differences in HbA1c, glucose and
C16SO were mostly related to the diabetes.
The diagnostic potential of these markers was analysed
in an ROC curve analysis (Fig. 3a,b). For the diagnosis of
the metabolic syndrome, doxSA and doxSO (Fig. 3a) had
AUCs of 0.875 and 0.842, respectively (p<0.001). More-
over, C16SO (Fig. 3b) showed an AUC of 0.282
(corresponding to 0.718; p<0.01).
Discussion
In this study, we compared the plasma sphingoid base
compositions of healthy individuals with those of individ-
uals with non-diabetic metabolic syndrome and diabetic
patients. We found dSLs to be significantly elevated in the
plasma of patients with either non-diabetic metabolic
syndrome or type 2 diabetes mellitus compared with
controls but not different between participants with non-
diabetic metabolic syndrome and diabetic patients. In
contrast, C16SO levels were lower in diabetic patients but
did not differ between controls and metabolic syndrome
patients. Other sphingoid base metabolites were not
different between the groups (Table 1).
These results indicate that the metabolic changes in the
metabolic syndrome and type 2 diabetes mellitus are
specifically associated with alterations in some, but not
all, sphingoid base species. Elevated dSL levels were also
confirmed in the plasma and liver tissue of a model of type 1
diabetes (STZ rats), indicating that the observed increase in
dSLs is independent of the type of diabetes.
Sphingolipid metabolism can be considered as a metabolic
cross point that interconnects fatty acid (acyl-CoA) and amino
acid (serine and alanine) metabolism. Serine and alanine
formation is thereby linked to glycolysis, which forms their
precursors, 3-phosphoglycerate and pyruvate, respectively.
The metabolic syndrome and type 2 diabetes mellitus are
associated with the clustering of several risk factors. To
delineate the relative contribution of each variable we used
a supervised learning approach (OPLS-DA) [24, 25]. This
analysis showed that dSL levels have, in addition to
triacylglycerols and HDL-cholesterol, the highest explana-
tory power for the metabolic syndrome. In this context it
has to be considered that the metabolic syndrome and type 2
diabetes mellitus are clinically not two completely separate
entities. Most diabetic patients also fulfil the criteria for the
metabolic syndromewhich, by itself, is associatedwith insulin
resistance. In fact, most diabetic patients have presented for
many years with the metabolic syndrome before hyper-
glycaemia has manifest. The observation that dSL levels are
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Fig. 3 ROC curves. (a) ROC curves for control vs metabolic
syndrome showing triacylglycerols and HDL-cholesterol as predictors
of the metabolic syndrome with AUCs of 0.968 (p<0.001) and 0.111
(corresponding to 0.889), respectively. The dSLs show comparable
AUCs, with 0.875 for doxSA and 0.842 for doxSO. Purple,
triacylglycerol; dark blue, HDL-cholesterol (reciprocal); green,
doxSO; light blue, doxSA; orange, waist circumference. (b) ROC
curves for potential biomarkers in metabolic syndrome vs diabetes.
HbA1c and glucose show AUCs of 0.939 and 0.917 for type 2
diabetes, whereas C16SO shows a significantly lower AUC of 0.282
(corresponding to 0.718), denoting its decrement in association with
diabetes. Green, glucose; light blue, HbA1c; dark blue, C16SO
(reciprocal)
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not different between non-diabetic metabolic syndrome
patients and diabetic patients suggests that the dSLs are
already formed in the prediabetic state in which insulin
insensitivity is still compensated by increased insulin produc-
tion and hyperinsulinaemia.
In contrast, C16SO together with glucose and HbA1c
were the strongest contributors in the diabetes model.
C16SO is generated by the use of myristoyl-CoA instead
of palmitoyl CoA—a reaction that is primarily catalysed by
the SPT long-chain base subunit 3 (SPTLC3) [13].
It should be noted at this point that we also found
significant levels of C17SO in the plasma samples analysed.
C17SO is considered to be an ‘unnatural’ sphingoid base and
therefore is sometimes used as an internal normalisation
standard in lipidomics. However, the identity of C17SO in
human plasma was validated by comparison with a
commercial synthetic C17SO standard and also reported
earlier by Quehenberger et al. [26]. This indicates that C17SO
has to be used with caution as an internal standard for plasma
samples.
Currently, we do not fully understand why plasma dSL
levels are increased in the metabolic syndrome and
diabetes. That dSLs are almost exclusively present in
VLDL and LDL but not HDL indicates that the dSLs in
plasma are primarily of hepatic origin [27]. This view is
supported by the observation that dSL levels were elevated
in liver and plasma of STZ rats but were not present in
skeletal muscle. A possible explanation for the increased
dSL formation might be an increased hepatic availability of
alanine. Recent reports show that lifestyle modifications in
the metabolic syndrome are associated with significant
changes in the plasma amino acid profiles [28]. In obese
individuals increases in skeletal muscle output of alanine
and hepatic uptake of alanine were seen while serine levels
were not changed [18]. Furthermore, hepatic glucose
uptake is primarily mediated by GLUT2 and hence is
insulin independent. Hyperglycaemic conditions are there-
fore associated with elevated hepatic glucose levels and an
increased glycolytic flux that increases the formation of
pyruvate and its anaerobic conversion to either lactate or
alanine. Elevated glucose levels could hence increase
hepatic alanine levels and thereby dSL generation. This model
implies that dSL levels are elevated independent of the type of
diabetes, which is supported by the observation that dSL
levels were also found to be elevated in the plasma and liver of
an animal model of type 1 diabetes (STZ rats). In both
conditions even short-term and transient fluctuations in
plasma glucose levels might be integrated over time leading
to increased formation of dSLs that, by themselves, might
have a slow turnover as they are not degraded by the canonical
sphingolipid catabolism.
Another interesting aspect is whether increased plasma
dSL levels as well as decreased plasma C16SO levels
contribute to the pathogenesis of diabetes and its compli-
cations. Genome-wide association studies have shown a
strong association of genetic SPTLC3 variants with
alterations in lipid metabolism [29] and increased risk
for myocardial infarction [30]. Therefore, lower C16SO
levels might be directly or indirectly related to the
increased risk of diabetic patients for developing cardio-
vascular complications.
Previously, we showed that the increased formation
of dSLs is the pathological cause of the inherited
neuropathy HSAN1 [15, 31]. Clinically, HSAN1 closely
resembles the diabetic peripheral neuropathy (DPN) that
occurs in about 60% of diabetic patients. Both conditions
have late onset, slow progression and length-dependent
axonopathy. All peripheral nerves are affected, including
pain fibre, motor neurons and autonomic nerves. The
degeneration of small sensory fibres results in the loss of
pain sensation, which in turn leads to painless injuries.
Furthermore, HSAN1 and DPN are both associated with
skin ulcers, which is not a common feature in other
peripheral neuropathies. Considering the neurotoxic prop-
erties of dSLs, it might therefore be conceivable that
higher levels of dSLs are not only interesting from the
biomarker perspective but also because dSLs are potential
pathogenic agents in the DPN. Interestingly, it has been
shown recently that serum triacylglycerols correlate with
the progression of the diabetic neuropathy [32]. In parallel
we observed a strong correlation of the dSLs and
triacylglycerol levels (ESM Fig. 2).
Taken together our results suggest that dSLs are
relevant biomarkers for both the metabolic syndrome
and type 2 diabetes mellitus, whereas C16SO bases seem
to be specifically lowered in diabetes, possibly reflecting
the risk for developing cardiovascular complications.
Therefore, a combination of these markers might help to
improve risk prediction and therapy monitoring in diabetic
patients. This could be especially relevant in the transition
from the prediabetic to the diabetic state. A limitation of
this study is the rather small group size. However, for a
pilot biomarker study it is valid to use small numbers as
long as type I and type II errors are considered carefully.
We showed p values in the order of 1×10−5 after the most
conservative correction for doxSA and doxSO, which
support rejection of the null hypothesis, that there is no
difference in their plasma levels between the different
groups. However, larger and ideally prospective follow-up
studies are needed to further validate the potential of these
metabolites and to explore their diagnostic and prognostic
value. Finally, a more detailed knowledge of the physio-
logical and pathophysiological properties of these metab-
olites is important to better understand the interplay
between sphingolipids, carbohydrate metabolism, insulin
resistance and diabetes.
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Appendix
Chemical nomenclature
C16SA or C16-D-erythro-
sphinganine
(2S,3R,4E)-2-
Aminohexadecan-1,3-diol
C17SA (2S,3R,4E)-2-
Aminoheptadecan-1,3-diol
C18SA (2S,3R,4E)-2-
Aminooctadecan-1,3-diol
C20SA (2S,3R,4E)-2-Aminoicosan-
1,3-diol
C16SO or C16D-erythro-
sphingosine
(2S,3R,4E)-2-Amino-4-
hexadecen-1,3-diol
C17SO (2S,3R,4E)-2-Amino-4-
heptadecen-1,3-diol
C18SO (2S,3R,4E)-2-Amino-4-
octadecen-1,3-diol
C20SO (2S,3R,4E)-2-Amino-4-icosen-
1,3-diol
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